An intriguing aspect is the so-called “APOC3 paradox”: gain-of-function variants not only markedly increase plasma triglycerides and pancreatitis risk but also frequently coexist with hepatic steatosis and insulin resistance, suggesting a more complex pathophysiology than impaired chylomicron clearance alone [52]. The gene discussed is APOC3; the disease is Hepatic steatosis.